Patient Financing Fees: The Procedure-Margin Test
On this page
Article Summary
Patient financing is worth a higher fee only if additional completed procedures replace the contribution lost on patients who would have paid anyway. In the hypothetical practice, moving 30 monthly $5,000 procedures from a 3% to an 8% fee cuts contribution by $250 per case, or $7,500 a month. At $2,600 contribution per added case, three extra completed cases are needed just to exceed the old contribution by $300. Count only completed, collected incremental treatment, and add capacity costs, settlement timing and refunds before expanding a financing promotion.
Financing can increase accepted treatment and reduce the margin on patients who would have paid anyway. A practice needs both numbers before choosing a more expensive promotional plan.
A cash-pay medical, dental, or plastic surgery practice has to ask whether additional completed cases justify the additional financing cost across everyone using the offer. Checking that financed cases remain profitable answers only half the question.
Start with contribution after clinical delivery costs. Financing a $5,000 procedure doesn't create $5,000 of profit.
Read the practice agreement and patient terms separately
The practice pays a merchant cost under its provider agreement. The patient borrows under a separate agreement. Approval rates, settlement, refunds, recourse, promotional terms, and fees can differ by product.
Use an actual current quote. There is no universal merchant rate for patient financing, and the hypothetical rates below are not provider prices.
Patient understanding matters independently of the margin model. The CFPB's May 2023 report discusses transparency and consumer risks in medical credit and installment financing. Its consumer guidance warns that deferred-interest promotions can create interest obligations when promotional conditions aren't met.
A profitable practice offer still needs accurate explanation and an appropriate patient process. Don't describe deferred interest as unconditional interest-free borrowing.
Compare a promotion with the real alternative
Consider a hypothetical practice currently completing 30 eligible procedures each month:
| Per completed procedure | Current payment mix | Proposed financing |
|---|---|---|
| Collected procedure price | $5,000 | $5,000 |
| Variable clinical delivery cost | ($2,000) | ($2,000) |
| Payment or financing fee | ($150), modeled at 3% | ($400), modeled at 8% |
| Contribution before fixed practice cost | $2,850 | $2,600 |
If all 30 existing cases move to the proposed plan, the practice loses $250 contribution per case, or $7,500 monthly.
Each additional case under the new plan contributes $2,600 before any new capacity cost. Replacing $7,500 therefore requires 2.89 additional cases. In practice, three extra completed, collected cases are needed merely to exceed the old contribution by $300.
At 33 cases, contribution is $85,800. The original 30 cases produced $85,500. A 10% increase in procedure volume has produced only $300 more contribution.
That can still be worthwhile for patient access or another explicit objective. It is a poor basis for claiming a substantial profit improvement.
Only count additional completed treatment
Financing applications are not incremental procedures. Approved applications aren't either. Track completed, collected treatment and compare it with what would reasonably have happened without the promotion.
Some patients would have used another payment method. Others may schedule earlier rather than increase the year's total procedures. Cancellations, refunds, and capacity constraints can erase an apparent conversion gain.
Run a bounded pilot with a documented baseline, comparable procedures, and consistent patient eligibility. Record the original payment preference where appropriate without pressuring the patient. Keep clinical recommendations separate from finance targets.
A free 20-minute Profit & Tax Leak Check can help locate the first pricing or margin assumption to examine in your practice. Rough procedure revenue and delivery-cost figures are enough; no documents are required.
Check the next case's capacity cost
The simple example assumes the practice can deliver three more procedures without additional fixed capacity. If it needs an extra paid session costing $2,000, three additional cases no longer preserve the old contribution.
The required incremental contribution becomes $9,500: $7,500 of fee dilution plus $2,000 for the extra session. Dividing by $2,600 requires 3.65 additional cases, so four are needed.
If clinical delivery cost also rises in the added session, recalculate the per-case contribution. Don't use a blended historical margin when the next procedure requires overtime or a more expensive facility slot.
The provider-capacity model provides that operating check. The patient lifetime-value article helps evaluate longer-term relationships, but uncertain future visits should not be used to hide a weak current procedure.
Add settlement and refund timing
Merchant cost is only one cash input. Confirm when the financing provider settles, what happens when treatment is postponed, and how refunds or disputes are deducted.
A larger upfront receipt can improve working capital while creating a future treatment obligation. Keep that cash separate from the question of when revenue is earned.
Measure the pilot by completed cases, contribution after fees, settlement timing, refunds, and patient complaints. If the promotional plan changes the mix toward expensive procedures, compare like with like before attributing the result to financing.
Choose the offer with visible tradeoffs
For plastic surgery practices and other cash-pay providers, fractional CFO support can connect financing terms with procedure contribution and available capacity.
The immediate decision is whether the offer produces enough additional treatment contribution to cover the cost paid on existing demand. Bring those two estimates to a Profit & Tax Leak Check before expanding the promotion.
Frequently asked questions
Are the 3% and 8% patient financing fees actual lender quotes?
No. They are hypothetical modeling assumptions, not provider prices, and there is no universal merchant rate for patient financing. Use the practice's current provider agreement and an actual quote for a real decision, because approval rates, settlement, refunds, recourse, and fees can differ by product.
Why can more financed procedures produce little added practice profit?
The practice may pay higher fees on patients who would have completed treatment anyway, so incremental cases must first replace that contribution loss. In the example, a 10% increase in procedure volume, from 30 to 33 cases, produces only $300 more monthly contribution.
How much contribution does a patient financing promotion lose on existing procedures?
In the example the fee rises from $150 to $400, so contribution falls $250 per $5,000 procedure, from $2,850 to $2,600. Across 30 existing monthly cases, that reduces contribution by $7,500 per month before any new procedures are counted.
How many extra financed procedures recover the higher financing fee cost?
At $2,600 contribution per additional case, replacing $7,500 requires 2.89 additional cases, so three extra completed, collected procedures are needed. At 33 cases, contribution is $85,800 against $85,500 originally, only $300 above the old result.
What if extra financed procedures need another paid clinical session?
With a $2,000 additional session cost, the required recovery becomes $9,500: $7,500 of fee dilution plus $2,000. Dividing by $2,600 requires 3.65 additional cases, so four are needed. If clinical delivery cost also rises in the added session, recalculate the per-case contribution.
Should patient financing applications count as incremental treatment?
No. Financing applications and approvals are not incremental procedures. Measure completed, collected treatment against what would reasonably have happened without the promotion, using a bounded pilot with a documented baseline, because payment-method switching, earlier scheduling, cancellations, and refunds can erase an apparent gain.
What should practice staff understand about deferred-interest patient financing?
Deferred interest is not unconditional interest-free borrowing. Consumer guidance warns it can create interest obligations when promotional conditions are not met. Explain the actual lender terms accurately, remember the patient borrows under a separate agreement, and keep clinical recommendations separate from finance targets.
Which patient financing cash terms matter beyond the merchant fee?
Confirm when the financing provider settles, what happens when treatment is postponed, how refunds and disputes are deducted, and any recourse. A larger upfront receipt can improve working capital while still carrying a future treatment obligation, so keep that cash separate from earned revenue.